Ganli Pharmaceutical (603087.SH): GLR1075 injection phase I clinical trial completed administration to the first test subject

Zhitong Finance App News, Ganli Pharmaceutical (603087.SH) announced that the GLR1075 injection independently developed by the company is undergoing phase I clinical trials in China, and recently successfully completed the administration of the first test subject.

GLR1075 injection is a recombinant human albumin preparation independently developed by Ganli Pharmaceutical. It is a humanized recombinant protein drug. Its active ingredient, recombinant human albumin, has the same amino acid sequence and similar spatial conformation as natural human serum albumin, and can perform the core physiological functions of albumin, including correcting colloidal osmotic pressure imbalance and improving the pathological microenvironment. This clinical trial is intended to develop indications for the treatment of liver cirrhosis, ascites, hypoalbuminemia.